North America Bovine Respiratory Disease Treatment Market

North America Bovine Respiratory Disease Treatment Market Size (2023 to 2032)

The North America Bovine Respiratory Disease Treatment Market was valued at USD 20.04 million in 2023. The North America Bovine Respiratory Disease Treatment Market is expected to have 18.3 % CAGR from 2024 to 2032 and be worth USD 90.94 million by 2032 from USD 23.71 million in 2024.

BRD refers to any disease of the lower or upper respiratory tracts in cattle and is commonly associated with lung infections, which can cause pneumonia. Bovine Respiratory Disease is far too common, far too costly, and, for the most part, seems far too hard to handle. If cattle are treated more than once, they never get back to that peak performance.

The disease is caused by various factors such as Host factors, which include animal age, immunity, genetics, and exposure to pathogens; environmental factors involve crowding, temperature, commingling and transport, Internal or external parasite infections, and Infectious agents. The weight loss that animal has due to BRD sickness will stay with them throughout the feeding period. Hence, productivity is reduced. Antibiotics and anti-inflammatory drugs are now being used for combination treatment and are expected to improve the treatment's success rate.

This research report segmented and sub-segmented the North America Bovine Respiratory Disease Treatment Market into the following categories

North America Bovine Respiratory Disease Treatment Market - By Treatment Type

• Anti-Infectious Agents

  • Antibiotics

  • Sulfas
• Anti-Parasiticides
• Bronchodilators
• Oral Rehydration Fluids
• Non-Steroidal Anti-Inflammatories
• Mucolytics

North America Bovine Respiratory Disease Treatment Market - By Country

• The United States

• Canada

• Rest of North America

KEY MARKET PLAYERS

Some of the promising companies operating in the North American Bovine Respiratory Disease Treatment Market are Zoetis Inc., Merck & Co. Inc., Bayer Corporation, Eli Lilly & Co, Merial S.A.S, Boehringer Ingelheim Vetmedica, Novartis Animal Health, Vibrac S.A., Ceva Sante Animale, and Vétoquinol S.A.